TABLE 2

Cell-based clinical trials using MSCs, MSC derivatives and other cells

Registration date and execution date range DD-MM-YYYYStudy phase and recruitment statusID and URLTitleCell typeTotal participants nIntervention or treatment
Clinical trials based on MSCs
114-02-2020; 20-02-2020 to 20-02-20210
Not recruiting
ChiCTR2000029816;
http://www.chictr.org.cn/showproj.aspx?proj=49389
Clinical study for cord blood mesenchymal stem cells in the treatment of acute novel coronavirus pneumonia (COVID-19)UCB-MSCs; UCB-NK cells60Experimental groups: conventional treatment followed by i.v. infusion of 1) UCB-MSCs and 2) UCB-MSCs combined with UCB-NK cells
Control group: conventional treatment
214-02-2020; 20-02-2020 to 20-02-20210
Not recruiting
ChiCTR2000029817;
http://www.chictr.org.cn/showproj.aspx?proj=49384
Clinical study of cord blood NK cells combined with cord blood mesenchymal stem cells in the treatment of acute novel coronavirus pneumonia (COVID-19)NK cells and UCB-MSCs60Experimental (high-dose) group: high-dose NK cells (>5×109) and MSCs (>5×109), i.v. infusion once every 2 days for a total of 5 times
Conventional dose group: conventional dose NK cells (>3×109) and MSCs (>3×109), i.v. infusion once every 2 days for a total of 3 times
Preventive dose group: preventive dose NK cells (>3×109) and MSCs (>3×109), i.v. infusion once every week for a total of 1 time
307-02-2020; 15-01-2020 to 31-12-20220
Recruiting
ChiCTR2000029606;
http://www.chictr.org.cn/showproj.aspx?proj=49146
Clinical study for human menstrual blood-derived stem cells in the treatment of acute novel coronavirus pneumonia (COVID-19)MenSCs63Experimental group A:
Conventional treatment followed by i.v.  infusion of MenSCs
Control group A: conventional treatment
Experimental group B:
1: Artificial liver therapy + conventional treatment
2: Artificial liver therapy followed by i.v. infusion of MenSCs + conventional treatment
Control group B: conventional treatment
407-02-2020; 06-02-2020 to 30-09-20202
Recruiting
NCT04269525;
https://clinicaltrials.gov/show/NCT04269525
Umbilical cord (UC)-derived mesenchymal stem cells (MSCs) treatment for the 2019-novel coronavirus (nCOV) pneumoniaUC-MSCs10Experimental group: UC-MSCs 3.3×107 cells per 50 mL per bag, 3 bags each time; UC-MSCs will be infused i.v. on the 1st, 3rd, 5th and 7th days after enrolment, once each day
Control group: none specified
505-02-2020; 31-01-2020 to 31-12-20200
Recruiting
ChiCTR2000029580;
http://www.chictr.org.cn/showproj.aspx?proj=49088
A prospective, single-blind, randomized controlled trial for ruxolitinib combined with mesenchymal stem cell infusion in the treatment of patients with severe 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP)MSCs70Experimental group: ruxolitinib combined with MSCs
Control group: routine treatment
627-01-2020; 21-01-2020 to 31-12-20211
Recruiting
NCT04252118;
https://clinicaltrials.gov/show/NCT04252118
Mesenchymal stem cell treatment for pneumonia patients infected with 2019 novel coronavirusMSCs20Experimental group: 3.0×107 MSCs i.v. at days 0, 3 and 6
Control group: none specified
714-02-2020; 16-02-2020 to 15-02-2022NA
Not recruiting
NCT04273646;
https://clinicaltrials.gov/ct2/show/NCT04273646
Study of human umbilical cord mesenchymal stem cells in the treatment of novel coronavirus severe pneumoniaUC-MSCs48Experimental group: 4 times of UC-MSCs, 0.5×106 UC-MSCs·kg−1 body weight i.v. at days 1, 3, 5 and 7
Control group: none specified
828-02-2020; 19-02-2020 to 20-02-20211
Recruiting
ChiCTR2000030300;
http://www.chictr.org.cn/showprojen.aspx?proj=50022
Umbilical cord mesenchymal stem cells (hucMSCs) in the treatment of high risk novel coronavirus pneumonia (COVID-19) patientsUC-MSCs9Experimental group: MSCs
Control group: none specified
926-02-2020; 14-02-2020 to 31-05-2020NA
Not recruiting
ChiCTR2000030224;
http://www.chictr.org.cn/showprojen.aspx?proj=49968
Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19)MSCs32Experimental group 1: critical group, intervention, injecting MSCs
Experimental group 2: severe group, intervention, injecting MSCs
Control group 3: control of the critical group, intervention, injecting normal saline
Control group 4: control of the severe group, intervention, injecting normal saline
1024-02-2020; 17-02-2020 to 17-04-20200
Not recruiting
ChiCTR2000030173;
http://www.chictr.org.cn/showprojen.aspx?proj=49229
Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstrationUC- MSCs60Experimental group: UC-MSCs
Control group: Conventional treatment
1124-02-2020; 24-02-2020 to 31-05-20202
Not recruiting
ChiCTR2000030138;
http://www.chictr.org.cn/showproj.aspx?proj=50004
Clinical trial for human mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)UC-MSCs60Experimental group: i.v. injection of UC-MSCs
Control group: routine treatment + placebo
1223-02-2020; 01-02-2020 to 31-08-2020NA
Recruiting
ChiCTR2000030116;
http://www.chictr.org.cn/showproj.aspx?proj=49901
Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)UC-MSCs16Experimental group: different stem cell doses
Control group: none specified
1322-02-2020; 01-03-2020 to 31-12-20210
Not recruiting
ChiCTR2000030088;
http://www.chictr.org.cn/showproj.aspx?proj=49902
Umbilical cord Wharton's jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)UC-Wharton's jelly MSCs40Experimental group: i.v. injection of Wharton's jelly MSCs (1×106 MSCs·kg−1), cell suspension volume 40 mL
Control group: i.v. 40 mL saline
1420-02-2020; 06-02-2020 to 05-02-2022NA
Recruiting
ChiCTR2000030020;
http://www.chictr.org.cn/showproj.aspx?proj=49812
The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)MSCs20Experimental group: case series, MSC therapy
Control group: none specified
1518-02-2020; 30-01-2020 to 31-03-20201–2
Recruiting
ChiCTR2000029990;
http://www.chictr.org.cn/showproj.aspx?proj=49674
Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19)MSCs120Experimental group: MSCs
Control group: saline
1628-02-2020; 28-02-2020 to 31-12-20211–2
Not recruiting
NCT04288102;
https://clinicaltrials.gov/ct2/show/NCT04288102
Treatment with mesenchymal stem cells for severe corona virus disease 2019 (COVID-19)MSCs45Experimental group: 3 times of MSCs; if body weight ≥70 kg, 4.0×107 cells each time; if body weight <70 kg, 3.0×107 cells each time; i.v. at days 0, 3 and 6
Control group: saline containing 1% human serum albumin (solution used for MSCs), 3 times of placebo, i.v. at days 0, 3 and 6
1724-02-2020; 24-02-2020 to 01-02-2021NA
Recruiting
NCT04293692;
https://clinicaltrials.gov/show/NCT04293692
Therapy for pneumonia patients infected by 2019 novel coronavirusUC-MSCs48Experimental group: conventional treatment plus 4 times of 0.5×106 UC-MSCs·kg−1 body weight suspended in 100 mL saline containing 1% human albumin, i.v. at days 1, 3, 5 and 7
Control group: conventional treatment plus 4 times of placebo (100 mL saline containing 1% human albumin), i.v. at days 1, 3, 5 and 7
Clinical trials based on MSC derivatives
104-02-2020; 05-02-2020 to 30-04-20210
Not recruiting
ChiCTR2000029569;
http://www.chictr.org.cn/showproj.aspx?proj=49062
Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trialUC-MSCs CM30Experimental group: conventional treatment combined with UC-MSCs CM
Control group: conventional treatment
219-02-2020; 15-02-2020 to 31-07-20201
Not recruiting
NCT04276987;
https://clinicaltrials.gov/ct2/show/NCT04276987
A pilot clinical study on inhalation of mesenchymal stem cells exosomes treating severe novel coronavirus pneumoniaAT-MSC exosomes30Experimental group: 5 times aerosol inhalation of MSC-derived exosomes, 2.0×108 nano vesicles per 3 mL at days 1, 2, 3, 4 and 5
Control group: none specified
326-02-2020; 28-02-2020 to 31-05-20200
Not recruiting
ChiCTR2000030261;
http://www.chictr.org.cn/showprojen.aspx?proj=49963
A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19)MSC exosomes26Experimental group: aerosol inhalation of exosomes
Control group: blank
403-03-2020; 31-01-2020 to 31-01-2021NA
Not recruiting
ChiCTR2000030484;
http://www.chictr.org.cn/showproj.aspx?proj=50263
UC-MSCs and exosomes treating patients with lung injury following novel coronavirus pneumonia (COVID-19)UC-MSCs and exosomes90Experimental groups:
Group 1: UC-MSCs i.v. 5×107 cells each time, once a week, twice per course
Group 2: UC-MSCs i.v. 5×107 cells each time, once a week, twice per course, a total of 2 courses; exosomes i.v. administration, 180 mg each time, once a day, 7 days per course, 2 courses in total
Control group: same amount of placebo (stem cell solvent)
Clinical trials based on other cell types
114-02-2020; 20-02-2020 to 20-02-20210
Not recruiting
ChiCTR2000029812;
http://www.chictr.org.cn/showproj.aspx?proj=49374
Clinical study for umbilical cord blood mononuclear cells in the treatment of acute novel coronavirus pneumonia (COVID-19)UCBMCs60Experimental group: conventional treatment followed by i.v. UCBMC preparations
Control group: conventional treatment
205-02-2020; 05-02-2020 to 30-04-20210
Recruiting
ChiCTR2000029572;
http://www.chictr.org.cn/showproj.aspx?proj=41760
Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled clinical trialUCBMCs30Experimental group: conventional treatment combined with UCBMCs
Control group: conventional treatment
317-02-2020; 24-02-2020 to 31-12-20241–2
Recruiting
NCT04276896;
https://clinicaltrials.gov/show/NCT04276896
Function and safety study of SARS-CoV-2 synthetic minigene vaccinesAutologous LV-DC vaccine or antigen-specific cytotoxic T-cells100Experimental group: 5×106 LV-DC vaccine or 1×108 cytotoxic T-cells as a single infusion via subcutaneous fluids or i.v. injection; may receive additional infusions
Control group: none specified
413-02-2020; 20-02-2020 to 30-12-20201
Recruiting
NCT04280224;
https://clinicaltrials.gov/show/NCT04280224
NK cells treatment for novel coronavirus pneumoniaNK cells30Experimental group: conventional treatment plus twice a week of NK cells (0.1–2×107 NK cells·kg−1 body weight)
Control group: conventional treatment
506-03-2020; 10-04-2020 to 10-11-20202
Not recruiting
NCT04299152;
https://clinicaltrials.gov/ct2/show/NCT04299152
Clinical application of stem cell educator therapy for the treatment of viral inflammation caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CB-SCs20Experimental group: combination product: stem cell educator-treated mononuclear cells apheresis therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SCs in vitro, and returns the “educated” autologous immune cells to the patient's circulation
Control group: conventional treatment: regular treatments, only addressing their symptoms, such as reducing fever and cough
628-02-2020; 01-03-2020 to 17-02-20210
Not recruiting
ChiCTR2000030088;
http://www.chictr.org.cn/showproj.aspx?proj=49779
Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19)CIK and NK cells90Experimental groups:
CIK group: UCB CIK cells (1.6×108 cells·kg−1) injected twice every other day
NK group: UCB NK cells (1.6×108 cells·kg−1) injected twice every other day
Control group: conventional therapy

MSCs: mesenchymal stem (stromal) cells; i.v.: intravenous; UCB: umbilical cord blood; NK: natural killer; MenSCs: mesenchymal stem cells derived from menstrual fluid; UC: umbilical cord; CM: conditioned medium; AT: adipose tissue; UCBMCs: umbilical cord blood-derived mononuclear cells; LV-DC: lentivirus dendritic cell; CB-SCs: cord blood stem cells; CIK: cytokine-induced killer.